ScreenerHero

IMCR Immunocore Holdings plc

NAS · US · Healthcare · Biotechnology · immunocore.com
29.41USD-0.47%Mkt Cap: 1.51B $P/E: —

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.51B USD
Enterprise Value1.08B USD
Revenue (TTM)430.78M USD
Gross Profit394.93M USD
Net Income (TTM)-35.51M USD
Revenue/Share8.50 USD
Last Price29.41 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees524
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-39.17
PEG—
EV/EBITDA1423.98
EV/Revenue2.50
P/S3.53
P/B3.62
EPS (TTM)-0.36
EPS (Forward)-0.75
52W Range
27.5514% of range40.72
52W High40.72 USD
52W Low27.55 USD
Profitability
Gross Margin98.73%
Oper. Margin-2.58%
EBITDA Margin0.17%
Profit Margin-8.88%
ROE-9.32%
ROA-3.33%
Growth
Revenue Growth18.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.71M USD
CapEx (TTM)4.34M USD
FCF Margin8.26%
FCF Yield2.35%
Net Debt-445.25M USD
Net Debt/EBITDA-588.96
Balance Sheet
Debt/Equity1.15
Current Ratio4.47
Quick Ratio4.15
Book Value/Sh8.15 USD
Cash/Share17.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)62.73 USD
Upside (mean)+113.3%
Target Range34.00 USD – 100.00 USD
34.00+113.3% to mean100.00
# Analysts11
Ownership
Shares Out.51.50M
Float45.83M
Insiders0.07%
Institutions103.16%
Short Interest
Short Ratio20.3d
Short % Float16.76%
Short % Out.15.09%
Shares Short7.77M
Short (prev mo.)7.90M
Technical
SMA 5033.86 (-13.1%)
SMA 20032.15 (-8.5%)
Beta0.81
S&P 52W Chg15.78%
Avg Vol (30d)415.65K
Avg Vol (10d)459.60K
Technical Indicators
RSI (14)26.8
MACD-1.3071
MACD Signal-1.1111
MACD Hist.-0.1960
BB Upper34.83 USD
BB Middle31.55 USD
BB Lower28.27 USD
BB Width20.77%
ATR (14)1.151 USD
Vol Ratio (20d)0.82x